The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed at fostering high-quality development in the biomedicine industry. The initiative seeks to propel Guangzhou’s biopharmaceutical sector to overcome challenges, enhance metropolitan coordination, and spearhead industry growth in the Greater Bay Area (GBA). The program extends substantial financial incentives, including rebates, cash payments, and subsidies, to entities registered in Guangzhou that engage in biopharmaceutical R&D, clinical trials, translational research, manufacturing, and service management. The scheme prioritizes Class 1 innovative drugs manufactured locally and not imported.
The financial support encompasses a spectrum of innovative R&D categories:
- Top biopharmaceutical projects led by globally influential scientific leaders could receive full chain support from a RMB 5 billion (USD 695 million) fund over five years, with a 1:1 cost-sharing ratio and dedicated service channels for land use, planning, and product import/export processes.
- Translational research and industrialization projects by national strategic scientific and technological forces may receive up to 30% of total investment, capped at RMB 100 million (USD 14 million) per project.
- Clinical trial research for independently developed biological products and Class 1 traditional Chinese medicines, among others, could receive staged funding of up to RMB 3 million, RMB 5 million, and RMB 10 million for Phase I, II, and III trials, respectively, with an annual cap of RMB 100 million per enterprise.
- Developers of Class III and Class II high-end medical devices could earn one-time rewards of up to RMB 8 million and RMB 2 million per category, respectively, not exceeding RMB 10 million annually per enterprise.
- Post-subsidy support of 10% of total project investment, up to RMB 50 million, is offered for biological products and medical devices that have achieved industrialization.
- Incentives for non-clinical research quality management certifications range from RMB 1 million to RMB 4 million, and a one-time reward of RMB 2 million for first-time AAALAC certifications.
- Contract research and development production service institutions could earn rewards of up to RMB 30 million, with additional rewards for drug clinical research institutions based on the number of new drug clinical trials completed annually.
The plan also proposes preferential treatment for innovative product approval, import, and hospital access, including the establishment of an integrated innovation consortium, encouragement for Class 3 medical institutions to form alliances, and support for cell and gene therapies. The import of R&D drugs will be streamlined, and a catalog of major innovative pharmaceutical products will be established with a reward system for procurement.
Guangzhou will focus on developing a high-end biopharmaceutical industry spatial layout with Guangzhou International Bio-Island as the core, promoting innovation incubation, talent introduction, and the construction of nodes in the national biological data center system. Efforts will also be made to support the development of the experimental animal industry and guide funds to invest in biomedicine.- Flcube.com
